Has drug therapy changed the natural history of Parkinson's disease?

被引:11
作者
Clarke, C. E. [1 ,2 ]
机构
[1] Sandwell & W Birmingham Hosp NHS Trust, City Hosp, Dept Neurol, Birmingham B18 7QH, W Midlands, England
[2] Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Med, Birmingham, W Midlands, England
关键词
Parkinson's disease; Natural history; Mortality; Treatment; Levodopa; DELAYED-START; MORTALITY; LEVODOPA; PROGRESSION; RASAGILINE; TRIALS;
D O I
10.1007/s00415-010-5716-z
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
This narrative review examines the effects of drug therapy on the natural history of Parkinson's disease In terms of modifying the underlying disease process, it is possible that immediate therapy, rather than deferred treatment, can have a positive effect on the underlying disease process However, it is unlikely that drug therapy has changed mortality from the condition and there is no evidence that It can delay the onset of non-motor features such as dementia and falls The beneficial effects of drug therapy on the motor symptoms of Parkinson's disease are unquestionable, but these are at the expense of short-term dopaminergic side effects, long-term motor complications, and impulse control disorders Major questions remain regarding which initial therapeutic approach should be taken which may possibly be answered by the ongoing PD MED trial The beneficial effects of drug therapy on the motor features of Parkinson's disease have had a fundamental impact on the suffering of patients The mainstay of these therapies continues to be levodopa, although it is now used at lower doses than in the past and in combination with other drug classes
引用
收藏
页码:S262 / S267
页数:6
相关论文
共 14 条
  • [1] Prevalence and characteristics of dementia in Parkinson disease - An 8-year prospective study
    Aarsland, D
    Andersen, K
    Larsen, JP
    Lolk, A
    Kragh-Sorensen, P
    [J]. ARCHIVES OF NEUROLOGY, 2003, 60 (03) : 387 - 392
  • [2] Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?
    Clarke, Carl E.
    [J]. MOVEMENT DISORDERS, 2008, 23 (06) : 784 - 789
  • [3] DOES LEVODOPA THERAPY DELAY DEATH IN PARKINSONS-DISEASE - A REVIEW OF THE EVIDENCE
    CLARKE, CE
    [J]. MOVEMENT DISORDERS, 1995, 10 (03) : 250 - 256
  • [4] MORTALITY FROM PARKINSONS-DISEASE IN ENGLAND AND WALES 1921-89
    CLARKE, CE
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1993, 56 (06) : 690 - 693
  • [5] Mortality from Parkinson's disease
    Clarke, CE
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 68 (02) : 254 - 255
  • [6] Fahn S, 2004, NEW ENGL J MED, V351, P2498
  • [7] PARKINSONISM - ONSET PROGRESSION AND MORTALITY
    HOEHN, MM
    YAHR, MD
    [J]. NEUROLOGY, 1967, 17 (05) : 427 - &
  • [8] Ives NJ, 2004, BMJ-BRIT MED J, V329, P593, DOI 10.1136/bmj.38184.606169.AE
  • [9] A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
    Olanow, C. Warren
    Rascol, Olivier
    Hauser, Robert
    Feigin, Paul D.
    Jankovic, Joseph
    Lang, Anthony
    Langston, William
    Melamed, Eldad
    Poewe, Werner
    Stocchi, Fabrizio
    Tolosa, Eduardo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (13) : 1268 - 1278
  • [10] Rationale for Delayed-Start Study of Pramipexole in Parkinson's Disease: The PROUD Study
    Schapira, Anthony H. V.
    Albrecht, Stefan
    Barone, Paolo
    Comella, Cynthia L.
    McDermott, Michael P.
    Mizuno, Yoshikuni
    Poewe, Werner
    Rascol, Olivier
    Marek, Kenneth
    [J]. MOVEMENT DISORDERS, 2010, 25 (11) : 1627 - 1632